Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSCs in MIS-C
NCT04549285Phase 1Withdrawn
- Sponsor
- Joanne Kurtzberg
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human cord tissue mesenchymal stromal cells in multisystem inflammatory syndrome (MIS), sponsored by Joanne Kurtzberg. Primary endpoints: Safety of the Investigational Product, hCT-MSCs, infusion reactions, Safety of the Investigational Product, hCT-MSCs, related adverse events and 1 more. Planned start Mar 2021; status: withdrawn.
02
Drugs
human cord tissue mesenchymal stromal cells
03
Conditions
multisystem inflammatory syndrome (MIS)
Beyond the preview
Go deeper on NCT04549285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549285.